Avantax Advisory Services Inc. raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 18.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 218,223 shares of the biopharmaceutical company's stock after acquiring an additional 33,423 shares during the period. Avantax Advisory Services Inc.'s holdings in Bristol-Myers Squibb were worth $12,343,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $29,000. Dunhill Financial LLC raised its position in shares of Bristol-Myers Squibb by 39.8% in the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 189 shares during the period. Comprehensive Financial Planning Inc. PA bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $34,000. Finally, Westend Capital Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 76.41% of the company's stock.
Shares of NYSE:BMY opened at $59.83 on Thursday. The stock has a market capitalization of $121.40 billion, a PE ratio of -13.54, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The company's 50-day moving average price is $57.69 and its two-hundred day moving average price is $55.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.15%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.
In other news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.09% of the company's stock.
A number of brokerages have recently weighed in on BMY. Truist Financial lifted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Daiwa America upgraded Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 13th. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Cantor Fitzgerald lifted their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Bank of America reissued a "neutral" rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus price target of $57.86.
View Our Latest Report on Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.